Peptide content comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Martinez (1977), 8th Virginia secretary of transportation and deputy administrator of the United States Maritime Administration David Paterson (1977), first African-American governor of New York Karl Dean (1978), mayor of Nashville Christopher Dell (1978), career diplomat, former US ambassador to Zimbabwe, Angola, and Kosovo Martin J. Dunn (1979), former mayor of Holyoke, Massachusetts and member of the Massachusetts Senate Jim McGreevey (1978), 53rd governor of New Jersey Andres Alonso (1979), former CEO of Baltimore City Public Schools Timothy Horrigan (1979), member of the New Hampshire House of Representatives Randal Quarles (1981), 15th under secretary of the treasury for domestic finance, chair of the Financial Stability Board and vice chairman of the Federal Reserve Andrew C. McCarthy (1981), assistant U.S. attorney and columnist for National Review Charles J. O'Byrne (1981), secretary to the governor of New York Michael Waldman (1982), speechwriter for president Clinton; president of the Brennan Center for Justice John Solecki (1982), U.S. official for the United Nations high commissioner for Refugees, kidnapped in Pakistan by the Balochistan Liberation United Front in 2009 Barack Obama (1983), 44th president of the United States and first African-American to hold the office; former senator from Illinois; winner of the 2009 Nobel Peace Prize Victor Cha (1983), foreign policy expert; President Bush's top advisor on North Korean affairs Jay Lefkowitz (1984), George W.
== Advantages and disadvantages == This laboratory technique has various advantages. First, these tests are relatively cheap, relatively straightforward and allow for real-time measurements. Additionally, the testing conditions can be easily adjusted to fit different experimental objectives. This approach also allows for a strong directional migratory response making quantifying data simple. One limitation of this assay is that there could be inconsistencies with the depth and size of the scratch. When the scratch is done manually, it's susceptible to 'ragged' edge boundaries, which make analyzing data more difficult. Also, the damage could physically damage the cells adjacent to the wound and create inaccurate wound size areas. This limitation is slowly becoming less of an issue with automated technologies. The Electric Cell Impendance Sensing assays utilize to prevent damage to the cells in the underlying extracellular matrix that can likely happen with the manual scratching approaches. Additionally, the Woundmaker makes fast and uniform wounds across various numbered well-plates options (96 or 384) and allows for high throughput screening, which is a major advantage for various medical research studies. Despite the new technology that is increasing this assay's accuracy and efficacy, there are still confounding factors that can skew the assay results, such as cell "crowding", cell/cell adhesion effects and matrix effects. Additionally, there is still mention with the problem of accumulation of cells at the edge of the scratch, making the cell densities uneven.
== Indications for use == Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure and a decreased need for repeated coronary artery revascularization in the first month following the procedure. Research also shows that this drug can be of use for patients with diabetes and chronic kidney disease. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize. Pediatric uses include treatment of Kawasaki disease.
== Education and career == Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard. He received his Executive MBA from the University of Oxford in 2024. He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center. Later, he became the Chief of Cardiology at the VA Boston Healthcare System and, subsequently, the Interventional Cardiovascular Programs executive director at Brigham and Women's Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. In 2012, he was appointed a professor of medicine at Harvard Medical School.
Sources: en.wikipedia.org
=== Governmental districts (Regierungsbezirke) === The large states of Baden-Württemberg, Bavaria, Hesse, and North Rhine-Westphalia are divided into governmental districts, or Regierungsbezirke. In Rhineland-Palatinate, these districts were abolished or re-organized on 1 January 2000, in Saxony-Anhalt on 1 January 2004, and in Lower Saxony on 1 January 2005. From 1990 until 2012, Saxony was divided into three districts (called Direktionsbezirke since 2008). In 2012, these districts' authorities were merged into one central authority, the Landesdirektion Sachsen.
The Shalwar kameez is Pakistan's national dress, worn in all provinces: Punjab, Sindh, Balochistan, Khyber Pakhtunkhwa, and Azad Kashmir. Each province has its own style. Pakistanis wear a variety of fabrics like silk, chiffon, and cotton. In addition to the national dress, men often wear domestically tailored suits and neckties, especially in offices, schools, and social gatherings. Pakistan's fashion industry has thrived, blending traditional and modern styles to create a unique cultural identity. Regional and traditional dress remain significant symbols of native tradition, evolving into both modern and purer forms. Organisations like the Pakistan Fashion Design Council in Lahore and the Fashion Pakistan Council in Karachi host events like PFDC Fashion Week and Fashion Pakistan Week. Pakistan's inaugural fashion week took place in November 2009.
Pharmacology can be applied within clinical sciences. Clinical pharmacology is the application of pharmacological methods and principles in the study of drugs in humans. An example of this is posology, which is the study of the dosage of medicines. Pharmacology is closely related to toxicology. Both pharmacology and toxicology are scientific disciplines that focus on understanding the properties and actions of chemicals. However, pharmacology emphasizes the therapeutic effects of chemicals, usually drugs or compounds that could become drugs, whereas toxicology is the study of chemical's adverse effects and risk assessment. Pharmacological knowledge is used to advise pharmacotherapy in medicine and pharmacy.
One such design has a curved electrostatic path so that the more energetic ions are forced round the outer part of the bend. Another such design incorporates an electrostatic mirror in which the more energetic ions penetrate more deeply before reflection. In both designs, the faster ions have a longer flight path to offset their increased velocity, and all ions of the same mass arrive at the detector simultaneously.
== Metabolism == The exact metabolic pathways of dimethocaine have not been researched, but the different metabolites have been examined in Wistar rats. After administration of dimethocaine, different metabolites have been found and identified in their urine. Due to these metabolites, different metabolic pathways could have been postulated. The main phase I reactions are ester hydrolysis, deethylation, hydroxylation of the aromatic system, or a combination of these three. The main phase II reactions are N-acetylation, glucuronidation and a combination of both. Different cytochrome P450 isozymes are involved in the initial steps of human metabolism. The N-acetylation is catalyzed by the NAT2 isozyme.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.